Annual Reports in Medicinal Chemistry

Personal Essay - Reflections on Medicinal Chemistry at Merck, West Point Paul S. Anderson - My Path in Seeking New Medicines Peter R. Bernstein - Tales of Drug Discovery M. Ross Johnson I. Central Nervous System Diseases Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts - Recent Developments in Targeting Neuroinflammation in Disease Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal - Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer's Disease Harrie J. M. Gijsen and François P. Bischoff - mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher - NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments Kamalesh B. Ruppa, Dalton King and Richard Olson - Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging Lei Zhang and Anabella Villalobos II. Cardiovascular and Metabolic Diseases Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey - Case History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler - AMPK Activation in Health and Disease Iyassu K. Sebhat and Robert W. Myers - Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome Juan C. Jaen, Jay P. Powers and Tim Sullivan - Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes Philip A. Carpino and David Hepworth III. Inflammatory Pulmonary and Gastrointestinal Diseases Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey - Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists Alaric J. Dyckman - Bifunctional Compounds for the Treatment of COPD Gary Phillips and Michael Salmon - Inflammatory Targets for the Treatment of Atherosclerosis Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi IV. Oncology Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia - Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook Paul F. Richardson - Small-Molecule Antagonists of Bcl-2 Family Proteins Sean P. Brown and Joshua P. Taygerly - Notch Pathway Modulators as Anti-Cancer Chemotherapeutics Vibhavari Sail and M. Kyle Hadden - Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda V. Infectious Diseases Section Editor: John Primeau, Westford, Massachusetts - Recent Advances in the Discovery of Dengue Virus Inhibitors Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand - Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB Pravin S. Shirude and Shahul Hameed - HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replication Complex Robert Hamatake, Andrew Maynard and Wieslaw M. Kazmierski VI. Topics in Biology Section Editor: John Lowe, JL3Pharma LLC, Stonington, Connecticut - Antibody-Drug Conjugates for Targeted Cancer Therapy Victor S. Goldmacher, Thomas Chittenden, Ravi V. J. Chari, Yelena V. Kovtun and John M. Lambert - 3D Cell Cultures: Mimicking in Vivo Tissues for Improved Predictability in Drug Discovery Indira Padmalayam and Mark J. Suto - Virally Encoded G Protein-Coupled Receptors: Overlooked Therapeutic Opportunities? Nuska Tschammer - Recent Advances in Wnt/b-Catenin Pathway Small Molecule Inhibitors Daniel D. Holsworth and Stefan Krauss VII. Topics in Drug Design and Discovery Section Editor: Peter R.